Table 1.

Baseline characteristics of studies included.

Study	Follow-up duration	N (n)	STEMI (n)	Mean age (y)	Male (%)	Hypertension (%)	Hyperlipidemia (%)	Diabetes (%)	Current smoking (%)	DES (%)	Stent length (mm)	Stent diameter (mm)
Aadat et al. 2019	348 ds	500/724	500/724	58.4 ± 11.4/57.0 ± 12.1	76.0/77.0	60/54	60.0/60.0	28.0/26.0	8.0/11.0	74.5/70.9	26.5 ± 8.5/22.5 ± 6.7	3.0 ± 0.3/3.1 ± 0.4
Gao et al. 2018	12 M	199/137	199/137	59.4 ± 10.9/61.0 ± 11.3	78.9/76.6	61.3/52.6	3.0/2.9	NA	62.3/66.4	100/100	30.84 ± 12.17/27.86 ± 10.11	NA
Karjalainen et al. 2017	5 Y	357/470	135/186	63.6 ± 11.3/62.5 ± 12.3	75.9/76.2	50.7/49.6	45.4/58.9	82.1/83.8	67.5/65.5	100/100	18.8 ± 5.3/17.8 ± 5.5	3.18 ± 0.44/3.12 ± 0.44
Tasal et al. 2013	6 M	214/191	214/191	57.5 ± 11.8/56.4 ± 13.0	73.4/75.9	30.8/30.4	49.5/52.9	18.7/22.5	41.2/35.5	100/100	23.4 ± 6.2/20.5 ± 5.9	2.9 ± 0.4/3.1 ± 0.4
Biswas et al. 2012	10.5 M	71/89	71/89	61.0 ± 12.6/62.9 ± 14.1	78.9/75.3	43.7/60.7	35.2/48.3	22.5/25.8	46.5/40.5	26.8/23.6	NA	NA
Zhang et al. 2010	12 M	586/772	316/413	61.7 ± 12.9/60.1 ± 12.7	62.8/63.0	67.2/63.9	NA	2.60/23.0	NA	57.9/48.6	NA	NA
Imori et al. 2016	2 Y	148/153	63/57	60.1 ± 12.7/61.0 ± 12.8	80.4/74.5	57.4/63.2	50.7/31.6	10.1/13.8	45.9/50.0	0	22.2 ± 5.4/18.3 ± 3.8	3.1 ± 0.4/3.1 ± 0.4
Wang et al. 2019	1 Y	228/114	228/114	61.7 ± 8.4/63.6 ± 6.8	68..9/76.3	41.2/46.5	18.4/14.9	26.8/22.8	43.9/69.3	NA	29.6 ± 7.1/23.7 ± 5.9	3.2 ± 1.7/3.1 ± 1.3
Qin et al. 2019	1 M	76/319	76/319	61.7 ± 12.3/60.0 ± 12.3	82.9/82.5	54.0/51.4	38.2/36.7	23.7/18.5	44.7/18.5	NA	NA	NA
Soylu et al. 2018	No	62/62	62/62	60.9 ± 13.2/60.2 ± 13.9	75.8/72.6	56.5/50.0	NA	30.6/27.4	59.7/58.1	100/100	26.75 ± 7.65/24.68 ± 7.35	3.04 ± 0.46/2.99 ± 0.44
Yamaji et al. 2017	No	73/118	73/118	59.4 ± 9.7/58.2 ± 10.4	80.8/83.5	39.7/39.8	NA	16.4/16.9	54.8/44.9	34.2/60.2	NA	NA

STEMI: ST-elevation myocardial infarction; DES: drug-eluting stent; D: day; M: month; Y: year; NA: not available.